Bausch + Lomb Corporation Common Shares (BLCO)

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below:

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex.* Built on decades of leadership in AREDS-based vitamins, PreserVision AREDS3 is the most advanced PreserVision formula, intended to support a broader range of people, including those in earlier stages.*

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite® Vision Enhancement System.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D “Teach-in” webinar series that provides deeper insights on the company’s robust and differentiated product pipeline.

Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026.

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q1 CY2026, with sales up 9.4% year on year to $1.24 billion. The company’...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results.

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before the bell. Here’s what to expect. Bausch + Lomb beat analysts’ reve...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company’s sustainability framework designed to guide future action and accountability.

Bausch Lomb BLCO Q2 2025 Earnings Transcript

Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript

Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care and lens care materials in the United States – the equivalent of about five backyard swimming pools worth of water.1,2

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European commercial availability of the preloaded enVista Envy full range of vision intraocular lens (IOL), which offers excellent dysphotopsia tolerance on the widely used enVista IOL platform.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and...